Ekso combines strong technical capabilities with meaningful regulatory achievements and a diversified product portfolio across medical and industrial uses. Its devices demonstrate solid gross margins, supported by a base of patents, software, and clinical know‑how. The balance sheet carries limited leverage, giving some protection from debt‑related stress. Growing reimbursement recognition, respected brand positioning in rehabilitation centers, and an active R&D pipeline all support the potential for future growth in a promising but still‑emerging field.

The most pressing risks are financial. The company is running sizable operating losses, burning cash, and holding a relatively small cash balance with a long history of accumulated deficits. Liquidity therefore depends on either improved operating performance or continued access to external capital, with dilution or unfavorable terms as possible consequences. Commercially, adoption may remain slower than hoped due to reimbursement, training, and budget constraints at customers, while competition from both current peers and potential new entrants is real. Finally, the proposed business combination and possible sale or separation of the exoskeleton business introduce strategic and execution risks around focus, governance, and long‑term commitment to the current product lines.

Ekso’s future sits at the intersection of strong technological promise and meaningful financial and strategic uncertainty. If the company or any future owner can convert its innovation, regulatory clearances, and reimbursement wins into broader market adoption while tightening cost structures, its financial profile could gradually improve. Conversely, continued cash burn without sufficient revenue growth may force further capital raises, restructuring, or shifts in strategic direction. The contemplated combination with a cloud and AI‑oriented business and potential divestiture of exoskeleton assets could significantly reshape the story, making the eventual outcome dependent not only on product success but also on corporate transactions and capital‑allocation decisions.